Related Experiment Video
Updated: Dec 12, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
Jihad Ben Gabr1, Hiba Bilal1, Kanish Mirchia1
1SUNY Upstate Medical University, Syracuse, NY, USA.
Abstract:
Drug-induced thrombotic microangiopathy (DITMA) is a secondary cause of thrombotic microangiopathy and a potentially fatal inflammatory disease. DITMA has been attributed to a variety of drugs, particularly chemotherapeutic and immunosuppressive agents. Prompt diagnosis is critical for survival and treatment necessitates withdrawal of the offending drug; however, many cases require further treatment including plasmapheresis, immunosuppression, and anticoagulation. In this article, we report a cutaneous biopsy-proven case of tacrolimus-induced DITMA, which was successfully treated with eculizumab after failing the conventional standard of care.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Venous Thrombosis III: Interprofessional Care
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

